Stephens Inc. AR Has $2.51 Million Stake in UiPath Inc. (NYSE:PATH)

Stephens Inc. AR boosted its holdings in UiPath Inc. (NYSE:PATHFree Report) by 8,519.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 100,931 shares of the healthcare company’s stock after purchasing an additional 99,760 shares during the quarter. Stephens Inc. AR’s holdings in UiPath were worth $2,507,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Royal London Asset Management Ltd. raised its position in shares of UiPath by 5.9% in the 3rd quarter. Royal London Asset Management Ltd. now owns 139,544 shares of the healthcare company’s stock valued at $2,388,000 after buying an additional 7,742 shares in the last quarter. Swiss National Bank raised its position in shares of UiPath by 4.9% in the 4th quarter. Swiss National Bank now owns 1,211,500 shares of the healthcare company’s stock valued at $30,094,000 after buying an additional 56,600 shares in the last quarter. Vestmark Advisory Solutions Inc. acquired a new position in shares of UiPath in the 4th quarter valued at approximately $15,543,000. O Shaughnessy Asset Management LLC acquired a new position in shares of UiPath in the 3rd quarter valued at approximately $203,000. Finally, Invesco Ltd. raised its position in shares of UiPath by 2.8% in the 3rd quarter. Invesco Ltd. now owns 399,181 shares of the healthcare company’s stock valued at $6,830,000 after buying an additional 10,863 shares in the last quarter. Institutional investors and hedge funds own 62.50% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on PATH shares. Barclays dropped their target price on shares of UiPath from $25.00 to $16.00 and set an “equal weight” rating for the company in a research report on Thursday, May 30th. Morgan Stanley lowered their price objective on shares of UiPath from $25.00 to $15.00 and set an “equal weight” rating for the company in a research report on Thursday, May 30th. Scotiabank lowered their price objective on shares of UiPath from $30.00 to $25.00 and set a “sector perform” rating for the company in a research report on Wednesday, May 29th. Evercore ISI lowered their price objective on shares of UiPath from $27.00 to $13.00 and set an “in-line” rating for the company in a research report on Thursday, May 30th. Finally, KeyCorp reiterated a “sector weight” rating on shares of UiPath in a research report on Thursday, May 30th. Sixteen analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, UiPath currently has a consensus rating of “Hold” and an average target price of $18.12.

View Our Latest Stock Report on UiPath

Insider Activity

In related news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the transaction, the chief financial officer now directly owns 660,762 shares of the company’s stock, valued at $14,312,104.92. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 96,000 shares of company stock valued at $2,023,440. 22.37% of the stock is currently owned by insiders.

UiPath Price Performance

PATH opened at $12.00 on Friday. UiPath Inc. has a fifty-two week low of $11.53 and a fifty-two week high of $27.87. The company’s 50 day moving average price is $18.84 and its two-hundred day moving average price is $21.81.

UiPath (NYSE:PATHGet Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.10. UiPath had a negative net margin of 6.41% and a negative return on equity of 2.97%. The company had revenue of $405.25 million for the quarter, compared to analyst estimates of $383.32 million. Equities research analysts predict that UiPath Inc. will post -0.2 EPS for the current year.

About UiPath

(Free Report)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.

Featured Articles

Institutional Ownership by Quarter for UiPath (NYSE:PATH)

Receive News & Ratings for UiPath Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UiPath and related companies with MarketBeat.com's FREE daily email newsletter.